이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Amarin 배당금

배당금 기준 확인 0/6

Amarin 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.13
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 06

Amarin Corporation: Small Signs Of Recovery May Not Be Enough

Apr 16

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Mar 12

Amarin: Sarissa Is Giving Me Hope Again

Jan 15

Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Jan 03

Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Nov 19

Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

Sep 27

We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Jul 18

Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?

Nov 11

Amarin gains as activist Sarissa starts process for special meeting to replace some board members

Oct 11

Amarin's Vazkepa medicine gets final guidance from UK body for reimbursement and use

Jul 13

Amarin extends losses after Stat report on cardiovascular therapy

Jun 30

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 AMRN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: AMRN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Amarin 시장 대비 배당 수익률

AMRN 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (AMRN)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (AMRN)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 AMRN 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 AMRN 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 AMRN 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: AMRN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Amarin 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Amarin Corporation plc's (NASDAQ:AMRN) 28% Dip In Price Shows Sentiment Is Matching Revenues

Amarin Corporation plc Announces Executive Changes

Amarin Corporation Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its ADSs Pursuant to Nasdaq Listing Rule 5450(a)(1)

Amarin Corporation plc Receives National Reimbursement for Vazkepa (Icosapent Ethyl) in Greece by Greek Ministry of Health

New minor risk - Profitability

Consensus EPS estimates fall by 26%

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS exceeds analyst expectations

Amarin Corporation plc (NasdaqGM:AMRN) announces an Equity Buyback for $50 million worth of its shares.

Amarin Corporation plc to Report Q1, 2024 Results on May 01, 2024

Amarin Corporation: Small Signs Of Recovery May Not Be Enough

Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding

Amarin Corporation plc, Annual General Meeting, Apr 18, 2024

Price target decreased by 42% to US$1.42

Amarin Corporation plc to Report Q4, 2023 Results on Feb 29, 2024

Amarin Regains Compliance with Nasdaq Listing Rule

Amarin: Sarissa Is Giving Me Hope Again

Amarin Corporation plc Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified

Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)

Now 21% undervalued after recent price drop

Amarin Corporation Receives Non-Compliance Notice from Nasdaq

Amarin Corporation Receives Non-Compliance Notice from Nasdaq

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Amarin Corporation plc Appoints Jonathan Provoost as New Executive Vice President, Chief Legal & Compliance Officer, Effective November 15, 2023

Amarin Corporation plc to Report Q3, 2023 Results on Nov 01, 2023

Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel

President recently bought US$312k worth of stock

Consensus EPS estimates fall by 16%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amarin Corporation plc to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$0.15 loss, revenue downgraded

We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth

Amarin Corporation plc, Annual General Meeting, Jul 21, 2023

Amarin Corporation plc, Annual General Meeting, Jun 21, 2023

Amarin Corporation plc Highlights New Data Providing Potential Mechanistic Insight into Vascepa(R)/Vazkepa(R) (Icosapent Ethyl)

Consensus EPS estimates fall by 11%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 24% to US$2.70

Consensus EPS estimates fall by 21%

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.02 profit in FY 2021)

Sarissa Capital Releases Investor Presentation to Shareholders of Amarin Corporation

Sarissa Capital Management Issues a Statement Regarding Amarin Corporation

Sarissa Capital Management Issues a Statement Regarding Amarin Corporation

Sarissa Capital Discloses its Views on Amarin Corporation

Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders with White Proxy Cards

Sarissa Capital Issues a Press Release to Shareholders of Amarin Corporation

Sarissa Capital Issues a Letter to Shareholders of Amarin Corporation

Sarissa Capital Issues a Social Media Post by Alexander J. Denner Relating to Amarin Corporation

Sarissa Capital Issues a presentation to Shareholders of Amarin Corporation

Sarissa Capital Issues an Investor Presentation to Shareholders of Amarin Corporation

Amarin Corporation plc, Annual General Meeting, Feb 28, 2023

Amarin Corporation Provides Information to Shareholders

Amarin Corporation plc Announces VAZKEPA (Icosapent Ethyl) Approved By Medsafe In New Zealand

Sarissa Capital Calls Out Amarin’s Sham Board Refreshment

Sarissa Capital Sends a Requisition Notice to Amarin Corporation

Sarissa Capital Sends a Requisition Notice to Amarin Corporation

Amarin Corporation plc Provides Revenue Guidance for the the Fourth Quarter and Full Year 2022

High number of new directors

Price target increased to US$3.57

Amarin Corporation plc Announces Board Changes

Amarin Corporation plc Enters into Settlement Agreement with Health Net, LLC

Amarin Corporation plc's Vazkepa (Icosapent Ethyl) Receives Regulatory Approval in Switzerland

Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia

Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?

Consensus estimates of losses per share improve by 24%

Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors

Amarin gains as activist Sarissa starts process for special meeting to replace some board members

Amarin Corporation plc Announces New Reduce-It(R) Data Show Vascepa(R)/Vazkepa(R) (Icosapent Ethyl) Reduced Stemi as Well as Other Mi Subtypes

Amarin down 21% on higher than normal daily volume

Amarin Corporation plc Announces New Research on the Effects of VASCEPA®/VAZKEPA at the European Society of Cardiology Congress

For Amarin, Something Wishful This Way Comes